Literature DB >> 33849916

Authors' Reply.

Steven Fishbane1, Mohamed A El-Shahawy2, Bui Pham Van3, Dustin J Little4.   

Abstract

Entities:  

Keywords:  anemia; chronic kidney disease; erythropoietin

Year:  2021        PMID： 33849916      PMCID： PMC8259632          DOI： 10.1681/ASN.2021030334

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   14.978


× No keyword cloud information.
  5 in total

1.  On the Increased Event Rate of Urinary Tract Infection and Pneumonia in CKD Patients Treated with Roxadustat for Anemia.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  J Am Soc Nephrol       Date:  2021-04-13       Impact factor: 14.978

2.  Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.

Authors:  Robert Provenzano; James Tumlin; Raja Zabaneh; James Chou; Stefan Hemmerich; Thomas B Neff; K-H Peony Yu
Journal:  J Clin Pharmacol       Date:  2020-06-30       Impact factor: 3.126

3.  Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.

Authors:  Robert Provenzano; Anatole Besarab; Steven Wright; Sohan Dua; Steven Zeig; Peter Nguyen; Lona Poole; Khalil G Saikali; Gopal Saha; Stefan Hemmerich; Lynda Szczech; K H Peony Yu; Thomas B Neff
Journal:  Am J Kidney Dis       Date:  2016-02-02       Impact factor: 8.860

4.  Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.

Authors:  Steven Fishbane; Mohamed A El-Shahawy; Roberto Pecoits-Filho; Bui Pham Van; Mark T Houser; Lars Frison; Dustin J Little; Nicolas J Guzman; Pablo E Pergola
Journal:  J Am Soc Nephrol       Date:  2021-02-10       Impact factor: 10.121

5.  In Mixed Lymphocyte Reaction, the Hypoxia-Inducible Factor Prolyl-Hydroxylase Inhibitor Roxadustat Suppresses Cellular and Humoral Alloimmunity.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Athanasios Mavropoulos; Evdokia Nikolaou; Georgios Filippidis; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2020-10-04       Impact factor: 4.291
  5 in total
  2 in total

Review 1.  Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Allison Jaure; Elisabeth M Hodson; Marinella Ruospo; Tess E Cooper; Deirdre Hahn; Valeria M Saglimbene; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-08-25

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat.

Authors:  David Czock; Frieder Keller
Journal:  Clin Pharmacokinet       Date:  2021-12-14       Impact factor: 5.577
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.